• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

金诺芬和活性氧抑制尤因肉瘤细胞中的蛋白质合成并调节PLK1蛋白水平。

Auranofin and reactive oxygen species inhibit protein synthesis and regulate the level of the PLK1 protein in Ewing sarcoma cells.

作者信息

Haight Joseph A, Koppenhafer Stacia L, Geary Elizabeth L, Gordon David J

机构信息

Carver College of Medicine, University of Iowa, Iowa City, IA, United States.

Department of Pediatrics, Division of Pediatric Hematology/Oncology, University of Iowa, Iowa City, IA, United States.

出版信息

Front Oncol. 2024 Jun 12;14:1394653. doi: 10.3389/fonc.2024.1394653. eCollection 2024.

DOI:10.3389/fonc.2024.1394653
PMID:38933441
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11199525/
Abstract

Novel therapeutic approaches are needed for the treatment of Ewing sarcoma tumors. We previously identified that Ewing sarcoma cell lines are sensitive to drugs that inhibit protein translation. However, translational and therapeutic approaches to inhibit protein synthesis in tumors are limited. In this work, we identified that reactive oxygen species, which are generated by a wide range of chemotherapy and other drugs, inhibit protein synthesis and reduce the level of critical proteins that support tumorigenesis in Ewing sarcoma cells. In particular, we identified that both hydrogen peroxide and auranofin, an inhibitor of thioredoxin reductase and regulator of oxidative stress and reactive oxygen species, activate the repressor of protein translation 4E-BP1 and reduce the levels of the oncogenic proteins RRM2 and PLK1 in Ewing and other sarcoma cell lines. These results provide novel insight into the mechanism of how ROS-inducing drugs target cancer cells via inhibition of protein translation and identify a mechanistic link between ROS and the DNA replication (RRM2) and cell cycle regulatory (PLK1) pathways.

摘要

尤因肉瘤肿瘤的治疗需要新的治疗方法。我们之前发现尤因肉瘤细胞系对抑制蛋白质翻译的药物敏感。然而,抑制肿瘤中蛋白质合成的翻译和治疗方法有限。在这项研究中,我们发现由多种化疗药物和其他药物产生的活性氧会抑制蛋白质合成,并降低支持尤因肉瘤细胞肿瘤发生的关键蛋白水平。特别是,我们发现过氧化氢和金诺芬(一种硫氧还蛋白还原酶抑制剂以及氧化应激和活性氧的调节剂)均可激活蛋白质翻译抑制因子4E-BP1,并降低尤因肉瘤细胞系和其他肉瘤细胞系中致癌蛋白RRM2和PLK1的水平。这些结果为活性氧诱导药物如何通过抑制蛋白质翻译靶向癌细胞的机制提供了新的见解,并确定了活性氧与DNA复制(RRM2)和细胞周期调节(PLK1)途径之间的机制联系。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35b6/11199525/c765419cc6ad/fonc-14-1394653-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35b6/11199525/f4c56c5bbd11/fonc-14-1394653-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35b6/11199525/0dd895f3b950/fonc-14-1394653-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35b6/11199525/e310d5e8c187/fonc-14-1394653-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35b6/11199525/f0d62ba88db9/fonc-14-1394653-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35b6/11199525/c765419cc6ad/fonc-14-1394653-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35b6/11199525/f4c56c5bbd11/fonc-14-1394653-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35b6/11199525/0dd895f3b950/fonc-14-1394653-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35b6/11199525/e310d5e8c187/fonc-14-1394653-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35b6/11199525/f0d62ba88db9/fonc-14-1394653-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35b6/11199525/c765419cc6ad/fonc-14-1394653-g005.jpg

相似文献

1
Auranofin and reactive oxygen species inhibit protein synthesis and regulate the level of the PLK1 protein in Ewing sarcoma cells.金诺芬和活性氧抑制尤因肉瘤细胞中的蛋白质合成并调节PLK1蛋白水平。
Front Oncol. 2024 Jun 12;14:1394653. doi: 10.3389/fonc.2024.1394653. eCollection 2024.
2
Auranofin and reactive oxygen species inhibit protein synthesis and regulate the level of the PLK1 protein in Ewing sarcoma cells.金诺芬和活性氧抑制尤因肉瘤细胞中的蛋白质合成并调节PLK1蛋白水平。
bioRxiv. 2024 May 15:2024.05.13.593567. doi: 10.1101/2024.05.13.593567.
3
The translational repressor 4E-BP1 regulates RRM2 levels and functions as a tumor suppressor in Ewing sarcoma tumors.翻译后文本:翻译抑制因子 4E-BP1 调节 RRM2 水平,并作为尤文肉瘤肿瘤中的肿瘤抑制因子发挥作用。
Oncogene. 2021 Jan;40(3):564-577. doi: 10.1038/s41388-020-01552-0. Epub 2020 Nov 15.
4
mTORC1/2 and Protein Translation Regulate Levels of CHK1 and the Sensitivity to CHK1 Inhibitors in Ewing Sarcoma Cells.mTORC1/2 和蛋白质翻译调节尤文肉瘤细胞中 CHK1 的水平和对 CHK1 抑制剂的敏感性。
Mol Cancer Ther. 2018 Dec;17(12):2676-2688. doi: 10.1158/1535-7163.MCT-18-0260. Epub 2018 Oct 3.
5
Activator Protein-1 (AP-1) Signaling Inhibits the Growth of Ewing Sarcoma Cells in Response to DNA Replication Stress.激活蛋白-1(AP-1)信号抑制尤文肉瘤细胞对 DNA 复制应激的生长。
Cancer Res Commun. 2023 Aug 17;3(8):1580-1593. doi: 10.1158/2767-9764.CRC-23-0268. eCollection 2023 Aug.
6
Inhibition of the ATR-CHK1 Pathway in Ewing Sarcoma Cells Causes DNA Damage and Apoptosis via the CDK2-Mediated Degradation of RRM2.抑制尤文肉瘤细胞中的 ATR-CHK1 通路会导致 DNA 损伤和细胞凋亡,这是通过 CDK2 介导的 RRM2 降解实现的。
Mol Cancer Res. 2020 Jan;18(1):91-104. doi: 10.1158/1541-7786.MCR-19-0585. Epub 2019 Oct 24.
7
In silico and in vitro drug screening identifies new therapeutic approaches for Ewing sarcoma.计算机模拟和体外药物筛选确定了尤因肉瘤的新治疗方法。
Oncotarget. 2017 Jan 17;8(3):4079-4095. doi: 10.18632/oncotarget.13385.
8
Eltrombopag inhibits the proliferation of Ewing sarcoma cells via iron chelation and impaired DNA replication.依鲁替尼通过螯合铁和损害 DNA 复制抑制尤文肉瘤细胞的增殖。
BMC Cancer. 2020 Nov 30;20(1):1171. doi: 10.1186/s12885-020-07668-6.
9
Gene expression signature based screening identifies ribonucleotide reductase as a candidate therapeutic target in Ewing sarcoma.基于基因表达特征的筛选将核糖核苷酸还原酶鉴定为尤因肉瘤的候选治疗靶点。
Oncotarget. 2016 Sep 27;7(39):63003-63019. doi: 10.18632/oncotarget.11416.
10
RNA helicase DDX3: a novel therapeutic target in Ewing sarcoma.RNA解旋酶DDX3:尤因肉瘤中的一个新型治疗靶点。
Oncogene. 2016 May 19;35(20):2574-83. doi: 10.1038/onc.2015.336. Epub 2015 Sep 14.

本文引用的文献

1
Synergistic lethality between auranofin-induced oxidative DNA damage and ATR inhibition in cancer cells.金诺芬诱导的氧化 DNA 损伤与 ATR 抑制在癌细胞中的协同致死作用。
Life Sci. 2023 Nov 1;332:122131. doi: 10.1016/j.lfs.2023.122131. Epub 2023 Sep 29.
2
Acute Oxidative Stress Can Paradoxically Suppress Human NRF2 Protein Synthesis by Inhibiting Global Protein Translation.急性氧化应激可通过抑制整体蛋白质翻译反常地抑制人类NRF2蛋白质合成。
Antioxidants (Basel). 2023 Sep 7;12(9):1735. doi: 10.3390/antiox12091735.
3
Cancer Metabolism: The Role of ROS in DNA Damage and Induction of Apoptosis in Cancer Cells.
癌症代谢:活性氧在癌细胞DNA损伤及凋亡诱导中的作用
Metabolites. 2023 Jun 27;13(7):796. doi: 10.3390/metabo13070796.
4
Systematic identification of anticancer drug targets reveals a nucleus-to-mitochondria ROS-sensing pathway.系统鉴定抗癌药物靶点揭示了细胞核到线粒体 ROS 感应途径。
Cell. 2023 May 25;186(11):2361-2379.e25. doi: 10.1016/j.cell.2023.04.026. Epub 2023 May 15.
5
Inhibitors of the PLK1 polo-box domain: drug design strategies and therapeutic opportunities in cancer.PLK1 帕罗盒结构域抑制剂:癌症治疗中的药物设计策略与治疗机遇
Expert Opin Drug Discov. 2023 Jan;18(1):65-81. doi: 10.1080/17460441.2023.2159942. Epub 2023 Jan 1.
6
Present and Future Perspective on PLK1 Inhibition in Cancer Treatment.癌症治疗中PLK1抑制的现状与未来展望。
Front Oncol. 2022 Jun 2;12:903016. doi: 10.3389/fonc.2022.903016. eCollection 2022.
7
Inhibitor of DNA binding 2 (ID2) regulates the expression of developmental genes and tumorigenesis in ewing sarcoma.DNA 结合抑制因子 2(ID2)调节尤文肉瘤中发育基因的表达和肿瘤发生。
Oncogene. 2022 May;41(20):2873-2884. doi: 10.1038/s41388-022-02310-0. Epub 2022 Apr 14.
8
Protein synthesis control in cancer: selectivity and therapeutic targeting.癌症中的蛋白质合成控制:选择性和治疗靶向。
EMBO J. 2022 Apr 19;41(8):e109823. doi: 10.15252/embj.2021109823. Epub 2022 Mar 22.
9
The gold complex auranofin: new perspectives for cancer therapy.金络合物金诺芬:癌症治疗的新视角。
Discov Oncol. 2021 Oct 20;12(1):42. doi: 10.1007/s12672-021-00439-0.
10
Upgrade of an old drug: Auranofin in innovative cancer therapies to overcome drug resistance and to increase drug effectiveness.老药升级:金诺芬在创新癌症疗法中克服耐药性和提高药物疗效。
Med Res Rev. 2022 May;42(3):1111-1146. doi: 10.1002/med.21872. Epub 2021 Dec 1.